[go: up one dir, main page]

MX2014001218A - Tratamiento de cancer de mama. - Google Patents

Tratamiento de cancer de mama.

Info

Publication number
MX2014001218A
MX2014001218A MX2014001218A MX2014001218A MX2014001218A MX 2014001218 A MX2014001218 A MX 2014001218A MX 2014001218 A MX2014001218 A MX 2014001218A MX 2014001218 A MX2014001218 A MX 2014001218A MX 2014001218 A MX2014001218 A MX 2014001218A
Authority
MX
Mexico
Prior art keywords
breast cancer
cancer treatment
compounds
triple negative
cancer cells
Prior art date
Application number
MX2014001218A
Other languages
English (en)
Other versions
MX359664B (es
Inventor
Andrew A Protter
Jennifer Richer
Dawn Cochrane
Original Assignee
Medivation Prostate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014001218(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Prostate Therapeutics Inc filed Critical Medivation Prostate Therapeutics Inc
Publication of MX2014001218A publication Critical patent/MX2014001218A/es
Publication of MX359664B publication Critical patent/MX359664B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente describe el uso de uno o más compuestos que caen dentro del alcance de una o más fórmulas estructurales I, II, II, IV, V, o VI para tratar cáncer de mama negativo triple. Los compuestos útiles par tratar cáncer de mama incluyen aquellos compuestos de las fórmulas I, II, II, IV, V, o VI que inhiben la proliferación de células de cáncer de mama y/o conducen a la muerte de células de cáncer de mama, especialmente cáncer de mama negativo triple.
MX2014001218A 2011-07-29 2012-07-27 Tratamiento de cáncer de mama. MX359664B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161513361P 2011-07-29 2011-07-29
PCT/US2012/048471 WO2013066440A1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer

Publications (2)

Publication Number Publication Date
MX2014001218A true MX2014001218A (es) 2014-08-22
MX359664B MX359664B (es) 2018-10-05

Family

ID=48192564

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001218A MX359664B (es) 2011-07-29 2012-07-27 Tratamiento de cáncer de mama.

Country Status (18)

Country Link
US (4) US9517229B2 (es)
EP (4) EP3791724A1 (es)
JP (2) JP6158180B2 (es)
KR (1) KR101923250B1 (es)
CN (1) CN103997894B (es)
BR (1) BR112014002200A2 (es)
CA (1) CA2843417C (es)
CY (1) CY1121038T1 (es)
DK (1) DK2739153T3 (es)
EA (1) EA028452B1 (es)
ES (1) ES2696074T3 (es)
HU (1) HUE040524T2 (es)
MX (1) MX359664B (es)
PH (1) PH12014500248B1 (es)
PL (1) PL2739153T3 (es)
PT (1) PT2739153T (es)
SI (1) SI2739153T1 (es)
WO (1) WO2013066440A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2739153T3 (en) * 2011-07-29 2018-12-03 Medivation Prostate Therapeutics Llc TREATMENT OF BREAST CANCER
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
UA117663C2 (uk) 2012-09-26 2018-09-10 Арагон Фармасьютікалз, Інк. Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
NZ629469A (en) * 2013-04-17 2017-05-26 Signal Pharm Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
JP6945587B2 (ja) * 2013-11-07 2021-10-06 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
WO2015069266A1 (en) * 2013-11-07 2015-05-14 Flynn Daniel L Methods for inhibiting tie2 kinase useful in the treatment of cancer
WO2015184145A1 (en) * 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
AU2015360767A1 (en) * 2014-12-12 2017-06-08 Medivation Prostate Therapeutics Llc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
WO2016141167A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Combination liposomal pharmaceutical formulations
EP3265063A4 (en) 2015-03-03 2018-11-07 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
MY198676A (en) 2017-06-22 2023-09-15 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
AU2019216351B2 (en) 2018-01-31 2024-07-25 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
CN111818915B (zh) 2018-01-31 2024-05-24 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CA3121199A1 (en) * 2018-11-30 2020-06-04 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
KR20250057151A (ko) 2019-12-30 2025-04-28 데시페라 파마슈티칼스, 엘엘씨 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의조성물
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
US20230296584A1 (en) * 2020-08-03 2023-09-21 Oncocyte Corporation Classifying tumors and predicting responsiveness
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
RS53967B1 (sr) 2005-05-13 2015-08-31 The Regents Of The University Of California Diaril hidantoin jedinjenja kao antagonisti receptora androgena za lečenje raka
EP1954708A4 (en) 2005-11-23 2009-05-13 Univ Utah Res Found Methods and compositions involving intrinsic genes
LT2656841T (lt) * 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
MX2008012492A (es) 2006-03-29 2008-12-12 Univ California Compuestos de diariltiohidantoina.
US8680291B2 (en) * 2007-10-26 2014-03-25 The Regents Of The University Of California Diarylhydantoin compounds
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
WO2009114534A1 (en) 2008-03-14 2009-09-17 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
PT2297359E (pt) 2008-05-30 2014-03-19 Univ North Carolina Perfis de expressão de genes para prognosticar resultados relativos ao cancro da mama
BRPI1007990A2 (pt) 2009-02-24 2015-09-01 Medivation Prostate Therapeutics Inc Compostos específicos de diaril-hidantoína e diariltioidantoína.
EP2416657A4 (en) 2009-04-09 2012-09-05 Medivation Prostate Therapeutics Inc COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF
WO2011022316A1 (en) 2009-08-20 2011-02-24 The Regents Of The University Of Colorado, A Body Corporate Mirnas dysregulated in triple-negative breast cancer
WO2011044327A1 (en) 2009-10-07 2011-04-14 Medivation Prostate Therapeutics, Inc. Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds
US9066963B2 (en) 2011-03-15 2015-06-30 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with anthracycline therapy
DK2739153T3 (en) * 2011-07-29 2018-12-03 Medivation Prostate Therapeutics Llc TREATMENT OF BREAST CANCER
AU2012345789B2 (en) 2011-11-30 2018-02-15 British Columbia Cancer Agency Branch Methods of treating breast cancer with taxane therapy
AU2013306380A1 (en) 2012-08-23 2015-03-05 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
WO2014075067A1 (en) 2012-11-12 2014-05-15 Nanostring Technologies, Inc. Methods to predict breast cancer outcome
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
AU2015360767A1 (en) 2014-12-12 2017-06-08 Medivation Prostate Therapeutics Llc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer

Also Published As

Publication number Publication date
CY1121038T1 (el) 2019-12-11
PH12014500248A1 (en) 2014-03-17
US20190262315A1 (en) 2019-08-29
US9517229B2 (en) 2016-12-13
EA028452B1 (ru) 2017-11-30
JP6158180B2 (ja) 2017-07-05
JP2017141269A (ja) 2017-08-17
US20170087132A1 (en) 2017-03-30
CA2843417C (en) 2018-08-21
EP2739153A1 (en) 2014-06-11
HUE040524T2 (hu) 2019-03-28
PL2739153T3 (pl) 2019-04-30
HK1198867A1 (en) 2015-06-19
DK2739153T3 (en) 2018-12-03
KR20140107174A (ko) 2014-09-04
CN103997894A (zh) 2014-08-20
WO2013066440A1 (en) 2013-05-10
EA201400178A1 (ru) 2014-11-28
ES2696074T3 (es) 2019-01-14
EP3791724A1 (en) 2021-03-17
HK1201413A1 (en) 2015-09-04
US20140296312A1 (en) 2014-10-02
SI2739153T1 (sl) 2018-12-31
MX359664B (es) 2018-10-05
WO2013066440A9 (en) 2013-07-18
PT2739153T (pt) 2018-11-28
CA2843417A1 (en) 2013-05-10
CN103997894B (zh) 2016-08-24
EP3430907A1 (en) 2019-01-23
EP2739153B1 (en) 2018-08-22
EP2739153A4 (en) 2015-03-11
BR112014002200A2 (pt) 2017-03-07
US20210069154A1 (en) 2021-03-11
EP3610731A1 (en) 2020-02-19
US10111861B2 (en) 2018-10-30
JP2014524934A (ja) 2014-09-25
KR101923250B1 (ko) 2018-11-28
PH12014500248B1 (en) 2018-08-31

Similar Documents

Publication Publication Date Title
MX2014001218A (es) Tratamiento de cancer de mama.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CL2020000215A1 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp.
DOP2019000266A (es) Inhibidores de pd-1/pd-l1
NI201900019A (es) Inhibidores de procesos metabólicos celulares
UY37124A (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
MX377384B (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
UY33883A (es) Novedosos derivados heterocíclicos
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CR20160022A (es) Compuestos de n,6-bis (aril o heteroaril) 1,3,5- triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento del cancer
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
CL2015001246A1 (es) Derivados de bendamustina y los metodos de su uso
CL2016001151A1 (es) Derivados de purina 2,6-sustituidos y su uso en el tratamiento de trastorno proliferativos.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2017004600A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
ECSP17010238A (es) Compuestos novedosos de pirimidina sustituidos
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
SG10201900564WA (en) Methods for treating cancer
MX377528B (es) Compuestos de platino funcionalizados con monomaleimida para la terapia del cáncer.
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: ARESCO TECHNOLOGIES, LLC

FG Grant or registration